InMed Pharmaceuticals (INM) Operating Expenses (2019 - 2026)

InMed Pharmaceuticals has reported Operating Expenses for 8 years, with the latest figure at $2.8 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 36.28% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $10.4 million, a 9.11% increase from a year earlier, with the FY2025 full-year figure at $9.7 million, up 3.83% from the prior year.
• Operating Expenses was $2.8 million for Q1 2026 at InMed Pharmaceuticals, up from $2.3 million in the prior quarter.
• The five-year high for Operating Expenses was $6.8 million in Q2 2022, with the low at $2.0 million in Q4 2023.
• Average Operating Expenses over 5 years is $2.8 million, with a median of $2.3 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 104.75% in 2022, then plunged 69.64% in 2023.
• Over 5 years, Operating Expenses stood at $2.3 million in 2022, then fell by 16.03% to $2.0 million in 2023, then jumped by 37.88% to $2.7 million in 2024, then slipped by 15.77% to $2.3 million in 2025, then climbed by 24.17% to $2.8 million in 2026.
• The last three Operating Expenses figures came in at $2.8 million (Q1 2026), $2.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.